← Back to Search

Unknown

AND017 for Kidney Anemia

Phase 2
Waitlist Available
Research Sponsored by Kind Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and at week 2, 4, 6, 8, 10, 12, 14, and 28 days after the last dose
Awards & highlights

Summary

This trial is studying a drug to see if it is safe and effective for patients with non-dialysis chronic kidney disease.

Eligible Conditions
  • Kidney Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and at week 3, 6, 9, 12, 14, and 28 days after the last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of rise in hemoglobin for each of 3 dose levels as compared with placebo from baseline to 5 weeks after TIW oral dosing
Safety Evaluations
Secondary outcome measures
Change from baseline in Hb
Change in hemoglobin levels from baseline to the mean of weeks 10-13
Cumulative incidence of lack of response over the entire treatment period
+12 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: AND017 Dose CExperimental Treatment1 Intervention
AND017 will be administrated orally at dose C
Group II: AND017 Dose BExperimental Treatment1 Intervention
AND017 will be administrated orally at dose B
Group III: AND017 Dose AExperimental Treatment1 Intervention
AND017 will be administrated orally at dose A
Group IV: PlaceboPlacebo Group1 Intervention
Placebo will be administrated orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AND017
2021
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Kind Pharmaceuticals LLCLead Sponsor
8 Previous Clinical Trials
472 Total Patients Enrolled
Yusha Zhu, MD PhDStudy DirectorKind Pharmaceuticals LLC
3 Previous Clinical Trials
153 Total Patients Enrolled
~31 spots leftby Jul 2025